Filing Details
- Accession Number:
- 0000950170-25-036420
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-10 16:43:50
- Reporting Period:
- 2025-03-06
- Filing Date:
- 2025-03-10
- Accepted Time:
- 2025-03-10 16:43:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1855608 | Hannah Valantine | C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-03-06 | 12,875 | $16.75 | 14,639 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-06 | 12,875 | $32.58 | 1,764 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2025-03-06 | 12,875 | $0.00 | 12,875 | $16.75 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
38,626 | 2033-06-21 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 3,433 | Indirect | By Spouse |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.
- Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.